2. Signaling Pathways
  3. Neuronal Signaling
  4. Glucosylceramide Synthase (GCS)

Glucosylceramide Synthase (GCS)

Glucosylceramide synthase (GCS), converting ceramide to glucosylceramide, catalyzes the first reaction of ceramide glycosylation in sphingolipid metabolism. This glycosylation by GCS is a critical step regulating the modulation of cellular activities by controlling ceramide and glycosphingolipids (GSLs). An increase of ceramide in response to stresses, such as chemotherapy, drives cells to proliferation arrest and apoptosis or autophagy; however, ceramide glycosylation promptly eliminates ceramide and consequently, these induced processes, thus protecting cancer cells. Furthermore, persistently enhanced ceramide glycosylation can increase GSLs, participating in selecting cancer cells to drug resistance. GCS is overexpressed in diverse drug-resistant cancer cells and in tumors of breast, colon, and leukemia that display poor response to chemotherapy. As ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis, inhibition of GCS sensitizes cancer cells to anticancer drugs and eradicates cancer stem cells.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-144267
    Glucosylceramide synthase-IN-2
    		98.62%
    Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-2
  • HY-144266
    TP-060
    		99.31%
    Glucosylceramide synthase-IN-1 (T-036), a chemical probe, a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research.
    TP-060
  • HY-116392H
    D,L-erythro-PDMP hydrochloride
    		Inhibitor 98.45%
    D,L-erythro-PDMP hydrochloride is an erythro isomer of PDMP. D,L-erythro-PDMP hydrochloride causes growth inhibition of cultured rabbit skin fibroblasts. PDMP is an effective inhibitor of UDP-glucose:ceramide glucosyltransferase.
    D,L-erythro-PDMP hydrochloride
  • HY-116535
    D-threo-PPMP hydrochloride
    		98.0%
    D-threo-PPMP hydrochloride is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP hydrochloride can block karyokinesis and reduce cyst production.
    D-threo-PPMP hydrochloride
  • HY-144270
    Glucosylceramide synthase-IN-3
    		99.11%
    Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research.
    Glucosylceramide synthase-IN-3
  • HY-110363
    Miglustat-d9 hydrochloride
    		99.4%
    Miglustat-d9 hydrochloride is the deuterium labeled Miglustat hydrochloride. Miglustat hydrochloride is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
    Miglustat-d<sub>9</sub> hydrochloride
  • HY-155715
    G43
    		Inhibitor 99.76%
    G43 is a potent, selective glucosyltransferase inhibitor, with the Kd of 3.7μM and 46.9 nM for GtfB and GtfC, respectively. G43 has antibacterial to S. mutans in vitro and in vivo, and can be used for dental caries study.
    G43
  • HY-116392E
    D-threo-PDMP
    		Inhibitor 99.50%
    D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP can be used to study diseases related to targeted glycosphingolipid metabolism.
    D-threo-PDMP
  • HY-E70179
    β-1,4-Glucuronyltransferase 1
    beta-1,4-Glucuronyltransferase 1 is a glucosyltransferase. beta-1,4-Glucuronyltransferase 1 transfers glucuronic acid towards both α and β anomers of xylose.
    β-1,4-Glucuronyltransferase 1
  • HY-E70059
    alpha-1,2-Fucosyltransferase (α1,2FucT)
    alpha-1,2-Fucosyltransferase (α1,2FucT), i.e., alpha 1, 2-fucosyltransferase, is often used in biochemical studies. alpha-1,2-Fucosyltransferase is a rate-limiting enzyme, can catalyze the synthesis of Lewis y (a cell membrane-associated carbohydrate antigen).
    alpha-1,2-Fucosyltransferase (α1,2FucT)
  • HY-155716
    G43-C3-TEG
    		Inhibitor
    G43-C3-TEG is a glycosyl-transferase inhibitor. G43-C3-TEG reduces the biofilm formation by decreasing the production of EPS (extracellular polysaccharides).
    G43-C3-TEG
  • HY-E70184
    α-N-Acetylglucosaminidase
    α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1) is a alpha-N-acetylglucosaminidase.
    α-N-Acetylglucosaminidase
  • HY-14885R
    Eliglustat (Standard)
    		Inhibitor
    Eliglustat (Standard) is the analytical standard of Eliglustat. This product is intended for research and analytical applications. Eliglustat is an specific, potent and orally active glucocerebroside synthase inhibitor with an IC50 of 24 nM.
    Eliglustat (Standard)
  • HY-156208
    C2 Adamantanyl galactosylceramide (d18:1/2:0)
    		Inhibitor
    C2 Adamantanyl galactosylceramide (AdaGalCer) (d18:1/2:0) is a bioactive sphingolipid. C2 Adamantanyl galactosylceramide (d18:1/2:0) stimulates glucocerebrosidase activity in vitro. C2 Adamantanyl galactosylceramide (d18:1/2:0) inhibits microsomal LacCer and Gb3 synthase, and inhibits cell sulfatide synthesis. C2 Adamantanyl galactosylceramide (d18:1/2:0) reduces glucosylceramide (GlcCer) levels in normal and lysosomal storage disease (LSD) cells. C2 Adamantanyl galactosylceramide (d18:1/2:0) acts as a substrate for A4GALT and is able to lower Gb3 levels with an IC50 concentration of 40 μM in fabry disease cells.
    C2 Adamantanyl galactosylceramide (d18:1/2:0)
  • HY-17020S
    Miglustat-d9
    Miglustat-d9 is the deuterium labeled Miglustat. Miglustat (N-Butyldeoxynojirimycin) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1).
    Miglustat-d<sub>9</sub>
  • HY-E70178
    Protein O-Glucosyltransferase 1
    Protein O-Glucosyltransferase 1 is a glucosyltransferase. Protein O-Glucosyltransferase 1 modifies Notch signaling by adding glucose to serine residues in Notch.
    Protein O-Glucosyltransferase 1
  • HY-116535C
    D-threo-PPMP
    D-threo-PPMP is a potent inhibitor of glucosylceramide (GlcCer) synthase. D-threo-PPMP can block karyokinesis and reduce cyst production.
    D-threo-PPMP
  • HY-181989
    CAIF
    		Inhibitor
    CAIF is an irreversible, selective allosteric covalent inhibitor of ucosyltransferase 8 (FUT8) with an IC50 of 5.7 μM. CAIF inhibits core fucosylation modification in cancer cells, and suppresses the invasion and migration of cancer cells. CAIF is applicable for cancer research.
    CAIF
  • HY-16743C
    Ibiglustat hydrochloride
    Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease.
    Ibiglustat hydrochloride
  • HY-116392G
    D,L-erythro-PDMP
    		Inhibitor
    D,L-erythro-PDMP is an erythro isomer of PDMP. D,L-erythro-PDMP causes growth inhibition of cultured rabbit skin fibroblasts. PDMP is an effective inhibitor of UDP-glucose:ceramide glucosyltransferase.
    D,L-erythro-PDMP
Cat. No. Product Name / Synonyms Application Reactivity